Shares of KALA BIO KALA have nosedived 88.3% in a month after the company announced the failure of a mid-stage study evaluating its only clinical pipeline candidate, KPI-012, for the treatment of ...
Fintel reports that on September 8, 2025, Mizuho initiated coverage of KALA BIO (NasdaqCM:KALA) with a Outperform recommendation. Analyst Price Forecast Suggests 29.69% Upside As of September 3, 2025, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback